Management of the antiplatelet therapy during the diagnosis of venous thromboembolism disease : A national survey of French general practitioners' compared to the French vascular physicians' management
Copyright © 2020 Elsevier Masson SAS. All rights reserved..
INTRODUCTION: Approximately 15% of patients treated by anticoagulant for a venous thromboembolic event are also treated with antiplatelet therapy; and this association increases the risk of bleeding. The aim of this survey was to evaluate general practitioner's management of antiplatelet therapy at the initiation of anticoagulation, and at six months compared to French vascular physicians' management.
METHODS: A questionnaire including 4 clinical situations was established and the physicians were asked to detail antiplatelet and anticoagulant therapy management. From September 2017 to December 2017, an e-mail invitation and a reminder were sent to members of the departmental councils who participated; 218 questionnaires were obtained.
RESULTS: Overall, 91.3% of physicians considered that there was an increased risk of bleeding when antiplatelet therapy is associated with anticoagulation. After initiating anticoagulation, 67% of respondents continued antiplatelet therapy, while 30% stopped. Three strategies were used: 49.0% of physicians maintained concomitant antiplatelet therapy with full-dose anticoagulant, both at anticoagulant initiation and at 6 months; 23% of physicians stopped antiplatelet therapy and prescribed full-dose anticoagulant at initiation and at 6 months; 12.4% of physicians prescribed antiplatelet therapy associated with reduced-dose anticoagulation at 6 months regardless of the strategy at anticoagulant initiation.
CONCLUSION: One third of general practitioners stopped antiplatelet therapy at the initiation of an anticoagulation for a venous thromboembolic event. Prospective controlled trials are needed to clarify the best way to treat these patients in this situation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Journal de medecine vasculaire - 45(2020), 3 vom: 01. Mai, Seite 107-113 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fayol, Antoine [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 14.09.2020 Date Revised 14.09.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jdmv.2020.04.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM309853893 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM309853893 | ||
| 003 | DE-627 | ||
| 005 | 20231225134824.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jdmv.2020.04.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM309853893 | ||
| 035 | |a (NLM)32402424 | ||
| 035 | |a (PII)S2542-4513(20)30256-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fayol, Antoine |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Management of the antiplatelet therapy during the diagnosis of venous thromboembolism disease |b A national survey of French general practitioners' compared to the French vascular physicians' management |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.09.2020 | ||
| 500 | |a Date Revised 14.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Masson SAS. All rights reserved. | ||
| 520 | |a INTRODUCTION: Approximately 15% of patients treated by anticoagulant for a venous thromboembolic event are also treated with antiplatelet therapy; and this association increases the risk of bleeding. The aim of this survey was to evaluate general practitioner's management of antiplatelet therapy at the initiation of anticoagulation, and at six months compared to French vascular physicians' management | ||
| 520 | |a METHODS: A questionnaire including 4 clinical situations was established and the physicians were asked to detail antiplatelet and anticoagulant therapy management. From September 2017 to December 2017, an e-mail invitation and a reminder were sent to members of the departmental councils who participated; 218 questionnaires were obtained | ||
| 520 | |a RESULTS: Overall, 91.3% of physicians considered that there was an increased risk of bleeding when antiplatelet therapy is associated with anticoagulation. After initiating anticoagulation, 67% of respondents continued antiplatelet therapy, while 30% stopped. Three strategies were used: 49.0% of physicians maintained concomitant antiplatelet therapy with full-dose anticoagulant, both at anticoagulant initiation and at 6 months; 23% of physicians stopped antiplatelet therapy and prescribed full-dose anticoagulant at initiation and at 6 months; 12.4% of physicians prescribed antiplatelet therapy associated with reduced-dose anticoagulation at 6 months regardless of the strategy at anticoagulant initiation | ||
| 520 | |a CONCLUSION: One third of general practitioners stopped antiplatelet therapy at the initiation of an anticoagulation for a venous thromboembolic event. Prospective controlled trials are needed to clarify the best way to treat these patients in this situation | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anticoagulation | |
| 650 | 4 | |a Antiplatelet therapy | |
| 650 | 4 | |a Venous thromboembolism disease | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 700 | 1 | |a Plaisance, Ludovic |e verfasserin |4 aut | |
| 700 | 1 | |a Poenou, Géraldine |e verfasserin |4 aut | |
| 700 | 1 | |a Helfer, Hélène |e verfasserin |4 aut | |
| 700 | 1 | |a Le Jeune, Sylvain |e verfasserin |4 aut | |
| 700 | 1 | |a Mahé, Isabelle |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal de medecine vasculaire |d 2017 |g 45(2020), 3 vom: 01. Mai, Seite 107-113 |w (DE-627)NLM26724729X |x 2542-4513 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2020 |g number:3 |g day:01 |g month:05 |g pages:107-113 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jdmv.2020.04.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2020 |e 3 |b 01 |c 05 |h 107-113 | ||